TRAIL and Interferon-alpha Act Synergistically to Induce Renal Cell Carcinoma Apoptosis

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2010 Jul 29

PMID 20663526

Citations 4

Authors

Peter E Clark

Dina A Polosukhina

Kenneth Gyabaah

Harold L Moses

Andrew Thorburn

Roy Zent

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite modern targeted therapy metastatic renal cell carcinoma remains a deadly disease. Interferon-alpha (Calbiochem(R)) is currently used to treat this condition, mainly combined with the targeted anti-vascular endothelial growth factor antibody bevacizumab. TRAIL (Apo2 ligand/tumor necrosis factor related apoptosis inducing ligand) (Calbiochem) is a novel antineoplastic agent now in early phase clinical trials. Interferon-alpha and TRAIL can act synergistically to kill cancer cells but to our knowledge this has never been tested in the context of renal cell carcinoma. We hypothesized that TRAIL and interferon-alpha could synergistically induce apoptosis in renal cell carcinoma cells.

Materials And Methods: We treated renal cell carcinoma cell lines with recombinant TRAIL and/or interferon-alpha. Viability and apoptosis were assessed by MTS assay, flow cytometry and Western blot. Synergy was confirmed by isobologram. Interferon-alpha induced changes in renal cell carcinoma cell signaling were assessed by Western blot, flow cytometry and enzyme-linked immunosorbent assay.

Results: TRAIL and interferon-alpha acted synergistically to increase apoptotic cell death in renal cell carcinoma cells. Interferon-alpha treatment altered the ability of cells to activate extracellular signal-regulated kinase while inhibiting extracellular signal-regulated kinase with UO126 abrogated TRAIL and interferon-alpha apoptotic synergy. Interferon-alpha did not induce changes in TRAIL or death receptor expression, or change other known mediators of the intrinsic and extrinsic apoptotic cascade in the cells.

Conclusions: TRAIL plus interferon-alpha synergistically induces apoptosis in renal cell carcinoma cells, which is due at least in part to interferon-alpha mediated changes in extracellular signal-regulated kinase activation. TRAIL and interferon-alpha combination therapy may be a novel approach to advanced renal cell carcinoma that warrants further testing in vivo.

Citing Articles

Interferon-α and its effects on cancer cell apoptosis.

Shi W, Yao X, Fu Y, Wang Y Oncol Lett. 2022; 24(1):235.

PMID: 35720476 PMC: 9185151. DOI: 10.3892/ol.2022.13355.

Curcumin Sensitizes Kidney Cancer Cells to TRAIL-Induced Apoptosis via ROS Mediated Activation of JNK-CHOP Pathway and Upregulation of DR4.

Obaidi I, Cassidy H, Ibanez Gaspar V, McCaul J, Higgins M, Halasz M Biology (Basel). 2020; 9(5).

PMID: 32370057 PMC: 7284747. DOI: 10.3390/biology9050092.

Blocking TRAIL-DR5 signaling with soluble DR5 alleviates acute kidney injury in a severely burned mouse model.

Leng X, Zhang Q, Chen Z, Wang D Int J Clin Exp Pathol. 2014; 7(6):3460-8.

PMID: 25031778 PMC: 4097225.

Bioinformatics analysis of the factors controlling type I IFN gene expression in autoimmune disease and virus-induced immunity.

Feng D, Barnes B Front Immunol. 2013; 4:291.

PMID: 24065968 PMC: 3776951. DOI: 10.3389/fimmu.2013.00291.

References

Chen Q, Gong B, Zhou A, Hsi E, Hussein M, Almasan A . Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001; 98(7):2183-92. PMC: 1350927. DOI: 10.1182/blood.v98.7.2183. View

Pitti R, Marsters S, Ruppert S, Donahue C, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271(22):12687-90. DOI: 10.1074/jbc.271.22.12687. View

LeBlanc H, Ashkenazi A . Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003; 10(1):66-75. DOI: 10.1038/sj.cdd.4401187. View

Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104(2):155-62. PMC: 408479. DOI: 10.1172/JCI6926. View

Walczak H, Miller R, Ariail K, Gliniak B, Griffith T, Kubin M . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157-63. DOI: 10.1038/5517. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Griffith T, Fialkov J, Scott D, Azuhata T, Williams R, Wall N . Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002; 62(11):3093-9. View

Lee W, Choi C, Cha S, Oh H, Kim- Y . Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res. 2005; 30(2):263-70. DOI: 10.1007/s11064-005-2449-y. View

Leong S, Cohen R, Gustafson D, Langer C, Camidge D, Padavic K . Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009; 27(26):4413-21. DOI: 10.1200/JCO.2008.21.7422. View

10.

Zhang L, Zhang X, Barrisford G, Olumi A . Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 2006; 251(1):146-57. DOI: 10.1016/j.canlet.2006.11.013. View

11.

Mongkolsapaya J, Grimes J, Chen N, Xu X, Stuart D, Jones E . Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol. 1999; 6(11):1048-53. DOI: 10.1038/14935. View

12.

Kim Y, Lee D, Jeong J, Guo Z, Lee Y . Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol. 2008; 75(10):1946-58. PMC: 2430102. DOI: 10.1016/j.bcp.2008.02.016. View

13.

Chawla-Sarkar M, Leaman D, Jacobs B, Borden E . IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol. 2002; 169(2):847-55. DOI: 10.4049/jimmunol.169.2.847. View

14.

Griffith T, Stokes B, Kucaba T, Earel Jr J, Vanoosten R, Brincks E . TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther. 2009; 9(1):9-19. PMC: 2727705. DOI: 10.2174/156652309787354612. View

15.

Li P, Wang X, Li N, Kong H, Guo Z, Liu S . Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med. 2006; 18(3):505-10. View

16.

Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M . Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res. 2003; 63(6):1365-70. View

17.

Rini B . Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009; 27(19):3225-34. DOI: 10.1200/JCO.2008.19.9836. View

18.

Song J, Lee Y . Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal. 2008; 20(5):892-906. PMC: 2483832. DOI: 10.1016/j.cellsig.2008.01.001. View

19.

Bouralexis S, Findlay D, Atkins G, Labrinidis A, Hay S, Evdokiou A . Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 2003; 89(1):206-14. PMC: 2394221. DOI: 10.1038/sj.bjc.6601021. View

20.

Bukowski R . Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001; 19(2):148-54. View